SCHEMBL4831225

SCHEMBL4831225

COP(=O)(Cc1ccc(NC(=O)/C=C/c2nncn2-c2ccc(F)cc2)cc1)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP1 P03956 4/20 0.38
MMP2 P08253 4/20 0.38
MMP9 P14780 4/20 0.38
EGFR P00533 1/20 0.38
MAOB P27338 1/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 3/20 0.38
POLB P06746 2/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ATM Q13315 2/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829325 0.91 BTK (0.40) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4831431 0.88 MMP1 (0.41) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4831419 0.88 MMP1 (0.41) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4834188 0.85 RAB9A (0.41) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4835333 0.79 ATM (0.41) LMNARAB9AKMT2AMAPTMEN1
SCHEMBL4831254 0.79 MAOB (0.47) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4831213 0.79 MAOB (0.47) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4829338 0.79 MAOB (0.44) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL4829317 0.79 MAOB (0.44) NPC1LMNARAB9ASMN1; SMN2MMP1
SCHEMBL27613043 0.78 MAOB (0.47) NPC1LMNARAB9ASMN1; SMN2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 NPC1 1170/4885LMNA 2405/4885RAB9A 4059/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 NPC1 1170/4885LMNA 2405/4885RAB9A 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.